About the seminar:

Breast cancer is a leading cause of death among women globally and is thereby a
major threat to women’s health. Five-year survival rates decrease drastically with late-stage
diagnosis, so early detection and treatment of breast cancer is vital for reducing mortality rates.
Conventional methods for breast cancer diagnosis based on imaging are costly and non-definitive, while gold standard biomarker-based methods are time consuming, expensive, and
require trained personnel to be carried out. Therefore, a low-cost, easy-to-use, fast, and reliable
test that can detect breast cancer early on to increase chances of survival must be developed.
Recently, electrochemical sensing platforms have become increasingly popular for point-of-care
applications due to their superior detection capabilities and ease of use compared to traditional
methods. However, electrochemical platforms for HER2 positive breast cancer diagnosis require
further development before implementation into clinical settings is feasible. Magneto-electrochemical sensing (MES) platforms, which combine magnetic bead manipulation for
immunoassay steps with electrochemical sensing, are viable options for the point-of-care
detection of HER2 positive breast cancer protein biomarkers, thereby facilitating disease
diagnosis. MES platforms have the potential to be applied to other cancer biomarkers, which will
enable timely diagnosis and prognosis across multiple cancer types.